我在那里看病人 (2)
我的评论
选择研究
-
HER2 overexpression in urothelial carcinoma with GATA3 and PPARG copy number gains.
肿瘤学家
-
Therapies After Progression on Enfortumab Vedotin and Pembrolizumab: Navigating Second-line Options for Metastatic Urothelial Carcinoma in the New Treatment Landscape.
欧洲泌尿外科焦点
-
Therapy Attrition and Lessons for Future Approaches to Treatment of Advanced Urothelial Cancer.
JAMA网络开放
临床试验
Abemaciclib Before 177Lu-PSMA-617 for the Treatment of Metastatic Castrate Resistant Prostate C...
If two or more patients in a cohort experience a dose-limiting toxicity (DLT), then the maximum tolerated dose (MTD)has been exceeded. The previous dose level will be considered MTD和推荐的第二阶段剂量. 每一个投资...
招聘
Enfortumab Vedotin and Pembrolizumab Combined With Radiotherapy in Muscle Invasive Bladder Canc...
The RP2D is the last dose cohort at which no more than one instance of a dose limiting toxicity (DLT) is observed among 6 participants treated. 如果是最大耐受剂量 (MTD) cannot be determined due to lack of DLT during the...
招聘
4.9